Sign up Australia
Proactive Investors - Run By Investors For Investors

Medical Australia Ltd posts 25% lift in top line revenue

Medical Australia Ltd posts 25% lift in top line revenue

Medical Australia (ASX:MLA) has lifted top line revenue by 25% to $14.8 million on the strength of a 12 month contribution from its animal health business.

Although the human healthcare business is the engine for MLA with $11.5 million in revenues for the 2014/15 financial year and a 15% improvement over 2014.

Organic growth opportunities for this appear sound for the human health business in the private sector as well as health department contracts and also from overseas expansion.

Overall, a net loss after tax was recorded of $216,879 compared to a profit of $105,241 for the previous period.

The company will either divest or dilute its interests in the animal healthcare business given significant investment in the business required.

The company said that development of a number of new treatments for dogs as well undertaking further validation studies at several universities should see a realisation of the carrying value of the animal health investment during the first half of the 2016 financial year.

The weakening Australian dollar against the U.S. dollar did not assist the results as over 80% of its human healthcare inventory is under USD denominated contracts. Mitigation of the effects on margins is being mapped out.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.



Register here to be notified of future MLA Company articles
View full MLA profile View Profile

Medical Australia Timeline

Related Articles

Cells
May 17 2017
Revenues are on the rise and the group’s efforts to bring in new business is delivering.
ventripoint_device.png
June 22 2017
The device can give accurate and rapid volumetric information about all four chambers of the heart
shutterstock_127456451.jpg
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use